US stocks fell as President Trump's rapid trade policy shifts kept investors on edge ahead of the next batch of corporate ...

US stocks fell as President Trump's rapid trade policy shifts kept investors on edge ahead of the next batch of corporate ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson & Johnson CEO Joaquin Duato said.

The most substantial impact comes from tariffs against China and retaliatory tariffs from China. Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.

Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

The costs will be felt primarily within the company’s medical technology unit, which makes a range of medical devices and surgical products.

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall Street ...

Stocks opened higher Tuesday, with tech and bank names leading the charge as investors welcomed a morning packed with strong earnings and fresh deal buzz. Big banks were in rally mode: Citigroup, Bank ...

The New Brunswick, N.J.-based company raised its full-year sales guidance to a range of $91 billion to $91.8 billion, from its prior outlook of $89.2 billion to $90 billion. It said its outlook ...

U.S. stock futures were little changed Tuesday after two back-to-back days of gains on cautious tariff optimism.